--- title: "Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)" nct_id: NCT02501473 overall_status: TERMINATED phase: PHASE1, PHASE2 sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) study_type: INTERVENTIONAL primary_condition: "Follicular Low Grade Non-Hodgkin's Lymphoma" canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02501473.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02501473" ct_last_update_post_date: 2020-09-09 last_seen_at: "2026-05-12T06:19:09.185Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142) **Official Title:** Phase 1/2 Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Patients With Follicular Non-Hodgkin's Lymphoma **NCT ID:** [NCT02501473](https://clinicaltrials.gov/study/NCT02501473) ## Key Facts - **Status:** TERMINATED - **Why Stopped:** Business reasons - **Phase:** PHASE1, PHASE2 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 52 - **Lead Sponsor:** Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) - **Collaborators:** Merck Sharp & Dohme LLC - **Conditions:** Follicular Low Grade Non-Hodgkin's Lymphoma - **Start Date:** 2016-02-03 - **Completion Date:** 2019-08-01 - **CT.gov Last Update:** 2020-09-09 ## Brief Summary This is a Phase 1/2 open label trial of G100 in participants with low grade Non-Hodgkin's Lymphoma (NHL). G100 is composed of glucopranosyl lipid A in a stable emulsion and is a potent TLR4 (toll-like receptor-4) agonist. G100 will be administered by direct injection (intratumorally) into tumors of low grade NHL with or without standard low dose radiation therapy. Preclinical models and clinical studies in other cancers such as Merkel cell carcinoma have demonstrated that G100 administered in this manner can alter the tumor microenvironment, activate dendritic cells, T cells and other immune cells and induce systemic anti-tumor immune responses. In this trial, the safety, immunogenicity, and preliminary clinical efficacy of G100 will be examined alone or with pembrolizumab. ## Detailed Description This is a multi-center Phase 1/2 open label trial of intratumoral G100 in participants with low grade NHL. Eligible participants with NHL will be enrolled and receive G100 to an accessible tumor mass. Clinical response will be evaluated in the injected tumor and systemic (abscopal) responses will be evaluated in distal areas involved with tumor. The study will be conducted in 5 parts. In Part 1, Dose Escalation, 2 sequentially enrolled cohorts of participants will be treated at one of 2 dose levels of G100 using a standard escalation design. In this portion of the study, both follicular and marginal zone NHL will be eligible. In Part 2, 2 groups of participants with follicular NHL may be examined. One group will be randomly assigned to receive either single agent G100 intratumorally at the maximum safe dose determined in Part 1 following local radiation or will receive the same treatment regimen sequentially administered with pembrolizumab. A second treatment group may be explored if the safety profile in Part 1 is acceptable. In this optional group, participants with injectable tumors of 4 cm or greater would be enrolled and treated with a higher dose of G100. In Part 3, expansion of a higher dose (20µg of G100) in participants with follicular NHL will be enrolled to receive local radiation therapy and intratumoral G100. In Part 4, Dose Escalation and Expansion, a dose of 20µg of G100 will be examined as a treatment of 1 or more tumors (up to 4) with pembrolizumab in order to establish safety and examine clinical and biomarker responses in participants receiving increasing total systemic doses of G100 and Part 5, will evaluate standard induction therapy with rituximab (anti-CD20) in combination of escalating doses of intratumoral G100 in single tumors. The primary goal of this study is to determine the safety and tolerability of different doses of G100 when administered by intratumoral injection. The development of anti-tumor immune responses and preliminary evidence of clinical responses in local and distal tumor sites will also be examined. ## Eligibility - **Minimum age:** 18 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: 1. Follicular low-grade NHL: * In Part 1-3: either treatment naïve (except for France) OR relapsed or refractory following at least one prior treatment. * In Part 4, enrollment is limited to relapsed OR refractory follicular NHL participants. * In Part 5, enrollment will include relapsed and refractory CD20+ follicular NHL following at least one but not more than 2 prior treatments. 2. Tumor mass(es) accessible for intratumoral injection * For Part 1-3, are being considered for local radiation therapy and at least one additional site of disease outside the radiation field for assessment of distal (abscopal) response. * For Part 4 and 5, radiation therapy is omitted. Measurable tumor mass(es) accessible for intratumoral injection must be present for treatment and assessment of response. 3. ≥ 18 years of age 4. Life expectancy of ≥ 6 months per the investigator 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 6. Electrocardiogram (ECG) without evidence of clinically significant arrhythmia or ischemia 7. If female of childbearing potential (FCBP), willing to undergo pregnancy testing and agrees to use two methods of birth control or is considered highly unlikely to conceive during the dosing period and for three months after last study treatment, or if receiving pembrolizumab, four months after last treatment 8. If male and sexually active with a FCBP, must agree to use highly effective contraception such as latex condom or is sterile (e.g. following a surgical procedure) during the dosing period and for three months after last study treatment, or if receiving pembrolizumab, four months after last treatment Exclusion Criteria: 1. Cancer therapies, including chemotherapy, radiation (non-study regimen related), biologics or kinase inhibitors, granulocyte-colony stimulating factor (G-CSF) or granulocyte/monocyte-colony stimulating factor (GM-CSF) within 4 weeks prior to the first scheduled G100 dose 2. Investigational therapy within 4 weeks prior to G100 dosing 3. Prior administration of other intratumoral immunotherapeutics 4. Inadequate organ function including: 1. Marrow: Peripheral blood leukocyte count (WBC) \< 3000/mm\^3, absolute neutrophil count ≤ 1500/mm\^3, platelets \< 75000/mm\^3, or hemoglobin \< 10 gm/dL 2. Hepatic: alanine aminotransferase (ALT), and aspartate aminotransferase (AST) \> 2.5 x Upper Limit of Normal (ULN), total serum bilirubin \> 1.5 x ULN (participants with Gilbert's Disease may be included if their total bilirubin is ≤3.0 mg/dL) 3. Renal: Creatinine \> 1.5x ULN 4. Other: INR (international normalized ratio) or partial thromboplastin time (PTT) \>1.5 x ULN 5. Significant immunosuppression from: 1. Concurrent, recent (≤ 4 weeks ago) or anticipated treatment with systemic corticosteroids at any dose, or 2. Other immunosuppressive medications such as methotrexate, cyclosporine, azathioprine or conditions such as common variable hypogammaglobulinemia 6. Pregnant or nursing 7. Myocardial infarction within 6 months of study initiation, active cardiac ischemia or New York Heart Association (NYHA) Grade III or IV heart failure 8. History of other cancer within 2 years (except non-melanoma cutaneous malignancies and cervical carcinoma in situ) 9. Recent (\<1 week ago) clinically significant infection, active tuberculosis or evidence of active hepatitis B, hepatitis C or HIV infection 10. Central nervous system involvement with lymphoma, including parenchymal and leptomeningeal disease. 11. Significant autoimmune disease, including active non-infectious pneumonitis, with the exception of alopecia, vitiligo, hypothyroidism or other conditions that have never been clinically active or were transient and have completely resolved and require no ongoing therapy 12. Psychiatric, other medical illness or other condition that in the opinion of the principal investigator (PI) prevents compliance with study procedures or ability to provide valid informed consent 13. History of significant adverse or allergic reaction to any component of G100 and, if enrolled in Part 2 or Part 4, pembrolizumab and/or any of its excipients, and if enrolled in Part 5, anti-CD20 antibodies including rituximab and/or any of its excipients 14. Use of anti-coagulant agents or history a significant bleeding diathesis. (If a superficial lymph node or subcutaneous mass is to be injected, participants on agents such as non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, or clopidogrel are eligible and these agents do not have to be withheld. For procedures with moderate or significant risk of bleeding, long-acting agents such as aspirin or clopidogrel should be discussed with the Medical Monitor and may need to be discontinued before G100 therapy. For participants enrolled in Part 2 or Part 4 with the potential to receive pembrolizumab: 15. History of (non-infectious) pneumonitis that required steroids or has current pneumonitis or interstitial lung disease 16. Received a live virus vaccine within 30 days of planned study start 17. Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years. (Participants who have had a transplant greater than 5 years ago are eligible as long as there are no symptoms of graft vs. host disease \[GVHD\]). 18. Has had an allogeneic tissue/solid organ transplant 19. Has received prior therapy with an anti-PD-1, anti-programmed death ligand (PD-L)1, or anti-PD-L2 agent or if the participant has previously participated in Merck MK-3475 clinical trials or was previously treated with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event. ``` ## Arms - **Part 1: Local Radiation + G100 5μg/tumor** (EXPERIMENTAL) — Part 1: Local radiation and G100 \[glucopyranosyl lipid A stable emulsion, GLA-SE\] at 5μg/tumor administered intratumorally (IT) into accessible tumors for up to 8 weeks. - **Part 1: Local Radiation + G100 10μg/tumor** (EXPERIMENTAL) — Part 1: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks. - **Part 2: Local Radiation + G100 10μg/tumor** (EXPERIMENTAL) — Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks. - **Part 2: Local Radiation + G100 10μg/tumor+Pembrolizumab 200mg** (EXPERIMENTAL) — Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years. - **Part 2: Local Radiation, G100 20 μg/tumor in Large Tumors** (EXPERIMENTAL) — Part 2: Local radiation and G100 at 20 μg/tumor administered IT into accessible large tumors \[injectable lymphoma mass(es) ≥ 4 cm in total size\] for up to 8 weeks. - **Part 3: Local Radiation + G100 20μg/tumor** (EXPERIMENTAL) — Part 3: Local radiation and G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks. - **Part 4: G100 20μg/tumor and pembrolizumab 200mg** (EXPERIMENTAL) — Part 4: G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks and pembrolizumab 200mg IV and administered Q3W for up to 2 years. - **Part 5: G100 + Rituximab 375mg/m^2** (EXPERIMENTAL) — Part 5: G100 at 20, 40, 60, or 80μg/tumor administered IT for up to 6 weeks and rituximab administered as an IV infusion at 375mg/m\^2 on Day 0 and then QW for up to 3 weeks. ## Interventions - **G100** (DRUG) — GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist - **Pembrolizumab** (DRUG) — PD-1 Inhibitor - **Rituximab** (DRUG) — Rituximab (anti-CD20 antibody) ## Primary Outcomes - **Number of Participants With an Adverse Event (AE)** _(time frame: Up to approximately 42 months)_ — An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. - **Number of Participants Who Discontinued Study Drug Due to an Adverse Event** _(time frame: Up to approximately 105 weeks)_ — An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. ## Secondary Outcomes - **Overall Response Rate (ORR) by Immune-related Response Criteria (irRC)** _(time frame: Up to approximately 42 months)_ - **Clinical Benefit Rate (CBR) Using Immune-related Response Criteria (irRC)** _(time frame: Up to approximately 42 months)_ - **Clinical Benefit Rate (CBR) Using International Working Group (IWG) Criteria** _(time frame: Up to approximately 42 months)_ - **Duration of Response (DOR) by Immune-related Response Criteria (irRC)** _(time frame: Up to approximately 42 months)_ - **Duration of Clinical Benefit by Immune-related Response Criteria (irRC)** _(time frame: Up to approximately 42 months)_ - **Progression-free Survival (PFS)** _(time frame: Up to approximately 42 months)_ - **Overall Survival (OS)** _(time frame: Up to approximately 42 months)_ - **Overall Tumor Response Based on irRC Abscopal Sites** _(time frame: Up to approximately 42 months)_ - **Time to Response for Complete Response and Partial Response Participants** _(time frame: Up to approximately 42 months)_ - **Time to Next Treatment (TTNT)** _(time frame: Up to approximately 42 months)_ ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.whyStopped` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `sponsor.collaborators` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT02501473.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT02501473* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*